title: [Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma].
abstract: To investigate prognostic factors of the T-cell non-Hodgkin's lymphoma (T-NHL), and to study the clinical efficacy of CHOPE plus L-asparaginase(L-ASP) regimen for T-NHL.
  
  
  
  Retrospective analyses were made of 61 T-NHL patients who were treated from July 2007 to August 2013. Randomly divided into two groups CHOPE and CHOPE+L group(Based on CHOPE, added with L-ASP on the 1st, 3rd, 5th, 7th, 9th and 11th day).
  
  
  
  Of the 61 patients evaluatd with the median survival was 22 (3-65) months,the complete remission rate was 52.50%, the partial remission rate 29.51%, and the response rate 80.01%. The complete remission rate was 57.89%, and the patial remission rate 84.21% in CHOPE+L and the complete remission rate 43.48%, the response rate 78.26% in CHOPE, respectively (both P>0.05). The 1-, 2-, and 5-year overall survival rates were 91.0%, 87.6% and 65.7% respectively (P>0.05). But the overall survival rate in CHOPE+L was significantly higher than that in CHOPE group in extranodal NK/T-cell lymphoma, nasal type (ENKTCL) (P<0.05). The analysis of the prognostic factors indicated that ENKTCL, the outside junction lesions, and the CR rate were poor factors with statistic significance in T-NHL.
  
  
  
  CHOPE+L regimen has better efficacy for ENKTCL, but whether CHOPE+L regimen is used in the treatment of T-NHL, large prospective clinical trials are worth for further investigation.
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: W L
authors.initials: WL
authors.lastname: Wan
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: M X
authors.initials: MX
authors.lastname: Zhu
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: W
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: X Y
authors.initials: XY
authors.lastname: Ke
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D057186:Comparative Effectiveness Research; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy* / Q000401:mortality*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000401:mortality*; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012074:Remission Induction / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone